<DOC>
	<DOCNO>NCT00144989</DOCNO>
	<brief_summary>To evaluate role 3 cycle irinotecan cisplatin patient limited-stage small-cell lung cancer receive one course etoposide cisplatin plus concurrent accelerate hyperfractionated thoracic irradiation .</brief_summary>
	<brief_title>A Study Comparing Irinotecan Cisplatin ( IP ) With Etoposide Cisplatin ( EP ) Following EP/TRT LD-SCLC</brief_title>
	<detailed_description>The Japan Clinical Oncology Group ( JCOG ) previously conduct randomized phase III trial compare irinotecan cisplatin ( IP ) EP patient extensive-stage SCLC . The response rate overall median survival significantly well IP , i.e . 84.4 % 12.8 month IP , versus 67.5 % 9.4 month EP , respectively . The 2-year survival rate 19.5 % IP 5.2 % EP ( 7 ) . These encouraging result prompt u explore use IP LSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1. cytologically , histologically proven smallcell lung cancer 2. limited disease 3. age 2070 year old 4. performance status 01 5. measurable disease 6. prior treatment smallcell lung cancer 7. history chemotherapy 8. adequate organ function 9. write informed consent 1. pericardial effusion 2. active concomitant malignancy 3. pregnant lactate woman 4. interstitial pneumonia/active lung fibrosis chest xray , watery diarrhea , intestinal obstruction paralysis , uncontrolled heart disease history myocardial infarction within previous 6 month , uncontrolled diabetes mellitus , active infection , psychological disease deem unacceptable inclusion study , longterm steroid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Small-cell lung cancer</keyword>
	<keyword>Limited-Stage Small-Cell Lung Cancer</keyword>
	<keyword>Combined modality therapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cisplatin</keyword>
</DOC>